Late diagnosed Wilson disease with hepatic and neurological manifestations

A 50‐year‐old woman was referred to our hospital due to liver dysfunction and progressive neurological symptoms. She had previously been diagnosed with nonalcoholic steatohepatitis (NASH). Ursodeoxycholic acid (UDCA) had effectively normalized her serum aminotransferase levels, however, she presented with loss of balance, dysarthria and difficulty in handwriting. Autoantibodies and hepatitis virus markers were negative. Serum ceruloplasmin and copper levels were noted to be 9 mg/dL and 32 µg/dL, respectively. The 24‐h urinary copper excretion was 331.8 µg/day. Kayser‐Fleischer ring was demonstrated. Histological examination of the liver revealed inflammatory infiltrate and fibrosis, and the hepatic copper concentration was 444.4 µg/g dry weight. We diagnosed her as having Wilson disease and started treatment with trientine. Immuohistochemistry for keratin 8 and p62 demonstrated Mallory‐Denk bodies. Many of the p62‐expressing cells were positive for 4‐Hydroxy‐2‐nonenal (HNE). Few Ki‐67‐positive hepatocytes were present in the liver. Wilson disease is one of the causes of NASH and UDCA may be a supportive therapeutic agent for Wilson disease. Cell proliferation is suppressed under copper‐loaded conditions and this phenomenon may be associated with the clinical course of Wilson disease.

[1]  G. Brewer Practical Recommendations and New Therapies for Wilson’s Disease , 1995, Drugs.

[2]  M. McMahon,et al.  p62/SQSTM1 Is a Target Gene for Transcription Factor NRF2 and Creates a Positive Feedback Loop by Inducing Antioxidant Response Element-driven Gene Transcription* , 2010, The Journal of Biological Chemistry.

[3]  W. Stremmel,et al.  Truncating mutations in the Wilson disease gene ATP7B are associated with very low serum ceruloplasmin oxidase activity and an early onset of Wilson disease , 2010, BMC gastroenterology.

[4]  Giuseppe Maggiore,et al.  Genotype-phenotype correlation in Italian children with Wilson's disease. , 2009, Journal of hepatology.

[5]  C. Hajdu,et al.  Wilson disease and hepatocellular carcinoma. , 2008, Gastroenterology & hepatology.

[6]  M. Omary,et al.  Autophagy activation by rapamycin eliminates mouse Mallory‐Denk bodies and blocks their proteasome inhibitor‐mediated formation , 2008, Hepatology.

[7]  M. Schilsky,et al.  Diagnosis and treatment of Wilson disease: An update , 2008, Hepatology.

[8]  C. Yurdaydın,et al.  Late-onset Wilson's disease. , 2007, Gastroenterology.

[9]  K. Ashkan,et al.  Wilson's disease , 2007, The Lancet.

[10]  E. Akpınar,et al.  Liver imaging findings of Wilson's disease. , 2007, European journal of radiology.

[11]  H. Tsukahara,et al.  Relationship Between Oxidative Stress and Antioxidant Systems in the Liver of Patients With Wilson Disease: Hepatic Manifestation in Wilson Disease as a Consequence of Augmented Oxidative Stress , 2006, Pediatric Research.

[12]  G. Arunodaya,et al.  Wilson’s disease: cranial MRI observations and clinical correlation , 2006, Neuroradiology.

[13]  M. Schaefer,et al.  Clinical presentation, diagnosis and long-term outcome of Wilson’s disease: a cohort study , 2006, Gut.

[14]  J. Borjigin,et al.  Wilson disease in septuagenarian siblings: Raising the bar for diagnosis , 2005, Hepatology.

[15]  A. Irisawa,et al.  Hepatocellular carcinoma associated with Wilson's disease. , 2004, Internal medicine.

[16]  K. Zatloukal,et al.  Immunohistochemical analysis of Mallory bodies in Wilsonian and non‐Wilsonian hepatic copper toxicosis , 2004, Hepatology.

[17]  M. Schilsky,et al.  A practice guideline on Wilson disease , 2003, Hepatology.

[18]  R. Tandon,et al.  Use of ursodeoxycholic acid in liver diseases , 2001, Journal of gastroenterology and hepatology.

[19]  M. Tanner,et al.  Copper toxicity affects proliferation and viability of human hepatoma cells (HepG2 line) , 2000, Human & experimental toxicology.

[20]  T. Kawaguchi,et al.  Role of ATP7B in biliary copper excretion in a human hepatoma cell line and normal rat hepatocytes. , 2000, Gastroenterology.

[21]  K. Kowdley Ursodeoxycholic acid therapy in hepatobiliary disease. , 2000, The American journal of medicine.

[22]  A. Thor,et al.  Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Boyer,et al.  Ursodeoxycholic acid in cholestasis: Potential mechanisms of action and therapeutic applications , 1998, Hepatology.

[24]  S. Toyokuni,et al.  Immunohistochemical detection of 4-hydroxy-2-nonenal-modified-protein adducts in human alcoholic liver diseases. , 1998, Alcoholism, clinical and experimental research.

[25]  T. Sugiyama,et al.  Restoration of Holoceruloplasmin Synthesis in LEC Rat after Infusion of Recombinant Adenovirus Bearing WND cDNA* , 1998, The Journal of Biological Chemistry.

[26]  I. Wilkinson,et al.  Cranial MR imaging in Wilson's disease. , 1996, AJR. American journal of roentgenology.

[27]  B. Neuschwander‐Tetri,et al.  Oxidant injury to hepatic mitochondria in patients with Wilson's disease and Bedlington terriers with copper toxicosis. , 1994, Gastroenterology.

[28]  J. Rommens,et al.  The Wilson disease gene is a putative copper transporting P–type ATPase similar to the Menkes gene , 1993, Nature Genetics.

[29]  J. Peppercorn,et al.  The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene , 1993, Nature Genetics.

[30]  J. Gitlin,et al.  Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. , 1993, Biochemical and biophysical research communications.

[31]  K. Tanikawa,et al.  Biliary Copper Excretion in Acutely and Chronically Copper‐loaded Rats , 1993, Hepatology.

[32]  H. Nazer,et al.  Wilson's Disease. , 1991, Annals of Saudi medicine.

[33]  I. Sternlieb,et al.  Prognosis of Wilsonian chronic active hepatitis. , 1991, Gastroenterology.

[34]  I. Sternlieb Perspectives on Wilson's disease , 1990, Hepatology.